European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1186-1191 , November 2009

Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer – 12-year single center experience

  • M.J. Pavlov

      Affiliations

    • Department for Colorectal Surgery, First Surgical University Hospital, Clinical Center of Serbia, Koste Todorovica 6, 11000 Belgrade, Serbia
    • ,
  • P.A. Kovacevic

      Affiliations

    • Department for Colorectal Surgery, First Surgical University Hospital, Clinical Center of Serbia, Koste Todorovica 6, 11000 Belgrade, Serbia
    • ,
  • M.S. Ceranic

      Affiliations

    • Department for Colorectal Surgery, First Surgical University Hospital, Clinical Center of Serbia, Koste Todorovica 6, 11000 Belgrade, Serbia
    • ,
  • A.B. Stamenkovic

      Affiliations

    • Department for Colorectal Surgery, First Surgical University Hospital, Clinical Center of Serbia, Koste Todorovica 6, 11000 Belgrade, Serbia
    • ,
  • A.M. Ivanovic

      Affiliations

    • Department for Radiology, First Surgical University Hospital, Clinical Center of Serbia, Koste Todorovica 6, Belgrade, Serbia
    • ,
  • D.M. Kecmanovic

      Affiliations

    • Department for Colorectal Surgery, First Surgical University Hospital, Clinical Center of Serbia, Koste Todorovica 6, 11000 Belgrade, Serbia
    • Corresponding Author InformationCorresponding author. Tel.: +381 11 361 5 654; fax: +381 11 361 5 655.

,Accepted 5 March 2009.

References 

  1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827–841
  2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29
  3. FIGO annual report 2001. J Epidemiol Biostat. 2001;6:1–184
  4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259
  5. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004 Jan–Feb;14(1):35–41
  6. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374
  7. In:  Sugarbaker PH editors. Peritoneal carcinomatosis. Principles of management. Boston: Kluver Academic; 1996;
  8. Sugarbaker PH. Peritonectomy procedure. Ann Surg. 1995;221:29–42
  9. Meigs JV. Ovarian tumors with endocrine significance. Ann Surg. 1935 Nov;102(5):834–848
  10. Meigs JV. Tumors of the female pelvic organs. New York, NY: Macmillan; 1934;
  11. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA. 1955;159:1704–1707
  12. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–104
  13. Hoskins WJ, Bundy BN, Thigpen TJ, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage 3 epithelial ovarian cancer: a Gynecologic Oncology Groups study. Gynecol Oncol. 1992;47:59–66
  14. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43
  15. Ryu KS, Kim JH, Ko HS, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Aug;94(2):325–332
  16. Eisenkop SM, Spirtos NM, Lin WCM. “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol. 2006;103:329–335
  17. Vaart PJM, Vange N, Zoetmulder FAN, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148–154
  18. Steller MA, Egorin MJ, Trimble EL, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43:106–114
  19. Nicoletto MO, Padrini R, Galeotti F, et al. Pharmacokinetics of hyperthermic intraperitoneal chemotherapy with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol. 2000;45:457–462
  20. Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006 Sep 15;94(4):316–324
  21. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41(2):147–154
  22. ten Bokkel Huinink WW, Heintz APM, Dubbelman R, Franklin H, Mcvie JG. Intraperitoneal carboplatina for refractory ovarian cancer: phase I study. In: Proceedings of the second international conference of intracavitary chemotherapy. San Diego; 1988. p. 47.
  23. Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancers. Cancer Res. 1982;42:4265–4269
  24. Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006 Aug;32(6):671–675[Epub 2006 Apr 18]

PII: S0748-7983(09)00082-1

doi: 10.1016/j.ejso.2009.03.004

European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1186-1191 , November 2009

Article Tools

* Image Usage & Resolution